I think we struck the right balance. As I said, for us intellectual property rights are extremely important. Here, in that sense, we wanted to have high protection. If you compare the situation of Canada with other developing, industrialized countries, they were not on the top of the protection. So we wanted to have this high protection also to enable research. As Canada has a lot of research companies, it will benefit from that.
As I indicated in my presentation, we do not think that it will have this kind of inflation of prices, so health is at the centre of this policy and also the interests of the consumer. So I think that the intellectual property, particularly for the drug market, struck the right balance.